NeuroEM is excited to announce that we have successfully raised $1,330,000 in our latest funding round, marking a significant milestone in our journey to revolutionize the treatment of cognitive decline. With over a decade of rigorous clinical research under our belt, our innovative Transcranial Electromagnetic Treatment leveraging Radio Frequencies TEMT-FT technology continues to redefine the landscape of neurodegenerative disease care. This capital influx will be strategically deployed to further enhance our research and development capabilities, accelerate the clinical trials necessary to validate our breakthrough technology, and expand our market presence. Our team, composed of leading scientists and dedicated healthcare professionals, is committed to providing safe, effective, and non-invasive treatment solutions that not only halt but potentially reverse the effects of cognitive deterioration. The funding will support the optimization of our proprietary technology and the scaling of our operations to meet growing demand from those affected by Alzheimer’s and other neurodegenerative conditions, as well as individuals seeking to maintain optimal cognitive health as they age. At NeuroEM, our mission has always been driven by hope—hope for a future where the burden of cognitive decline is significantly diminished, and quality of life is vastly improved. This financial boost reaffirms the confidence our investors have in our vision and technological prowess. As we move forward, we remain steadfast in our commitment to scientific excellence, innovation, and compassionate care, transforming lives and offering new possibilities for those impacted by cognitive disorders.
NeuroEM Secures $1.33M Series A to Revolutionize Cognitive Health with Groundbreaking TEMT-FT Technology
Recently funded · $1.3M Series aHealthcare
Get the full NeuroEM company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
